Skip to main content
Premium Trial:

Request an Annual Quote

Drug Discovery Startup Engine Biosciences Raises $10M

NEW YORK (GenomeWeb) – Drug discovery startup Engine Biosciences announced today that it has raised $10 million in seed funding.

The oversubscribed round was co-led by Danhua Capital and 6 Dimensions Capital, and included WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI Harper, and Nest Bio Ventures.

Engine said it would use the funding to continue development of its drug discovery platform, which combines high-throughput wet lab experimentation with artificial intelligence algorithms, as well as to expand its scientific and executive teams in Singapore and San Francisco. The company also aims to conduct preclinical studies internally and with partners.

"Engine's data-driven platform allows researchers to uncover the critical gene interactions underlying diseases and also test therapies that specifically target these interactions in a faster, cheaper, and more precise fashion than currently possible," Engine Cofounder and CEO Jeffrey Lu said in a statement.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.